

Present:

Dr T Perren	Breast NSSG Representative
Dr J Dent	Colorectal NSSG Representative
Dr R Johnson	Haematology NSSG Representative
Ms J Craig	Health Economist (York Health Economics Consortium)
Dr M Snee	Lung NSSG Representative
Mr G Fell (Chair)	NHS Bradford & Airedale
Mrs S Frier	NHS Leeds
Mr P Allen	User Partnership Group
Mr P McManus	Yorkshire and The Humber SCG
Mr D Thomson	Yorkshire Cancer Network

Apologies

Professor D Dodwell, Ms G Fox, Mr J Hancock, Dr D Jackson, Ms A Johnson, Dr A O'Shaughnessy

1. Welcome and Apologies			
Log No	Action	Lead(s)	Deadline
76	G Fell welcomed the group and apologies were noted. Introductions were made around the table. G Fell welcomed Peter Allen. Peter will be the User Representative on the group.	N/A	N/A
2. Action Log from the last meeting			
Log No	Action	Lead(s)	Deadline
77	The action log from the meeting held on 30th September 2009 was agreed as an accurate record.	N/A	N/A
3. Matters arising			
Log No	Action	Lead(s)	Deadline
78	Update from log no. 61. 'Sunitinib Post Trial' issue still unresolved regarding access treatment costs . It was understood that Sean Duffy was planning to contact Kevin Smith with input from David Thomson and Greg Fell.	S Duffy	27/01/2010
79	D Thomson raised that Catherine Hughes at LHTH had suggested that the Gateway Group provide patient information in the form of a decision summary as part of the review for negative decisions. With the view to help patients understand how and why the decisions are made and for patients to make an informed choice whether to receive the treatment privately. David Thomson to discuss with Colin Sloane, User Involvement Facilitator at the YCN. J Craig raised that it may be useful to explore the feasibility of involving a medical writer. J Craig to forward contact details to D Thomson.	D Thomson & J Craig	27/01/2009

4. New topic proposals - Docetaxel in head and neck cancer			
Log No	Action	Lead(s)	Deadline
80	<p>D Thomson discussed the Docetaxel in head and neck cancer nomination from LTHT.</p> <p>It was agreed to await the SCG position from the Tri-Network forum as a similar proposal had been submitted. It was therefore agreed Docetaxel in head and neck cancer would not be added to the Gateway Group work programme as the drug is already been funded via IFR's and is on the Tri-Network forum agenda.</p> <p>D Thomson also tabled a nomination for Romiplostin from Claire Hall, Consultant Haematologist at Harrogate. It is anticipated that NICE will publish the guidance in February-April 2010. Due to timescales Romiplostin would not be added to the Gateway Group work programme.</p> <p>G Fell requested that he, R Johnson and J Hancock discuss Romiplostin and similar cases further outside the Gateway Group, with the view of having a position agreed without having a full review.</p>	N/A	N/A
5. Topics under review			
5.1 Gefitinib in mutation positive NSCLC - 1st line			
Log No	Action	Lead(s)	Deadline
81	<p>D Thomson informed the group that the final clinical review paper was now available for discussion.</p> <p>M Snee discussed in detail the NICE approved pathway. It was highlighted that Astra Zeneca are currently covering the additional costs of the mutation testing via pathology.</p> <p>J Craig and D Thomson to produce the budget impact model that reflects more accurately on the actual pathway rather than the pathway based on AZ's comparators. M Snee's to provide input.</p> <p>Amended budget impact model to be circulated to the clinicians then for discussion at the next meeting.</p>	J Craig & M Snee	27/01/2010
82	S Frier to feedback to NHS Leeds and other commissioning colleagues across the Network regarding implications for pathology departments.	S Frier	27/01/2010
83	D Thomson to send clinical review to DTC's for discussion and decision.	D Thomson	09/12/2010
5.2 Herceptin beyond progression in metastatic breast cancer			
Log No	Action	Lead(s)	Deadline
84	<p>D Thomson informed the group that the London Cancer New Drugs Group (LCNDG) have now undertaken the consultation review. Health economics review currently being discussed with J Craig. It is anticipated that the final documentation will be available within the next couple of weeks.</p> <p>It was agreed that due to this being considered standard practice in YCN there would be no need for the review to go to DTC's prior to discussion at the next meeting.</p> <p>D Thomson to circulate final papers once available. YCN breast clinicians to bring their comments to the next meeting.</p> <p>Topic is being discussed at a breast Tri-Network meeting scheduled for 4th January 2010.</p>	D Thomson	For Discussion at the Next Meeting

6. Topics at N3/SCG			
6.1 Everolimus in metastatic RCC - 2nd line			
Log No	Action	Lead(s)	Deadline
85	<p>J Craig to provide an update at the next meeting once she has completed the analysis of the Novartis model which was received after the last meeting.</p> <p>P McManus highlighted that the papers have been submitted to North Trent Cancer Network and will be discussed on 26th November within a commissioning forum. Humber and Yorkshire Coast Cancer Network have not sent any views.</p> <p>G Fell informed the group that J Craig is in the process of producing a dummies guide to health economic reviews.</p>	J Craig	27/01/2010
6.2 Bevacizumab in metastatic breast cancer - 1st line			
Log No	Action	Lead(s)	Deadline
86	<p>P McManus highlighted that the papers have been submitted to North Trent Cancer Network and will be discussed on 26th November within a commissioning forum. Humber and Yorkshire Coast Cancer Network have not sent any views.</p>	N/A	N/A
7. N3 Tri-Network Forum update			
Log No	Action	Lead(s)	Deadline
87	<p>Nothing new to update as the next meeting is scheduled to take place on 17th December 2009. Key items on the agenda are; horizon scanning and from that agreeing priorities and workstreams working in collaboration with the 3 Networks.</p>	N/A	N/A
8. Specialist Commissioning Group update			
Log No	Action	Lead(s)	Deadline
88	<p>P McManus gave an update from the last SCG Meeting. Topotecan in cervical cancer was presented based on the NICE guidance. Topotecan in lung cancer is been discussed at the next meeting again based on the recently published NICE guidance.</p> <p>P McManus raised that the impact of 'access schemes' is an ongoing unresolved issue.</p>	N/A	N/A
9. NICE update			
Log No	Action	Lead(s)	Deadline
89	<p>D Thomson tabled an update paper regarding recommendations from NICE and discussed recent published guidance.</p> <p>D Thomson to circulate to the Gateway Group for information.</p>	D Thomson	09/12/2009
10. Horizon scanning			
Log No	Action	Lead(s)	Deadline
90	<p>D Thomson raised that the Gateway Group needs to prioritise future recommendations. Presentations from the Gateway Launch to be utilised.</p>	D Thomson	27/01/2010

Gateway Group : Actions of the meeting held on Wednesday 25th November 2009 2:00pm

11. AOB			
Log No	Action	Lead(s)	Deadline
91	G Fell agreed to contact the PCT Chief Executives regarding PCT representation on the Gateway Group.	G Fell	27/01/2010
92	D Thomson agreed to circulate the feedback from the Gateway Launch Event held on 16th October 2009.	D Thomson	27/01/2009
93	G Fell and D Thomson agreed to contact Rob Webster regarding an interim decision framework for outstanding proposals. P McManus agreed to inform the SCG of the YCN's interim recommendations.	D Thomson & G Fell	27/01/2009

Date of Next Meeting(s)

Wednesday 27th January 2010 2:00pm
Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital

Wednesday 17th March 2010 2:00pm
Board Room, Ground Floor, Trust HQ, St James's University Hospital

Wednesday 19th May 2010 2:00pm
Seminar Room 2, Cookridge Suite, Level 7, Bexley Wing, St James's University Hospital

Wednesday 21st July 2010 2:00pm
Board Room, Ground Floor, Trust HQ, St James's University Hospital

Wednesday 22nd September 2010 2:00pm
Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital

Wednesday 17th November 2010 2:00pm
Seminar Room 2, Cookridge Suite, Level 7, Bexley Wing, St James's University Hospital